학술논문
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
Document Type
Article
Author
Source
In ESMO Open February 2022 7(1)
Subject
Language
ISSN
2059-7029